Article citationsMore>>

Huang, L., Wang, R., Xie, K., Zhang, J., Tao, F., Pi, C., Feng, Y., Gu, H. and Fang, J. (2022) A HER2 Target Antibody Drug Conjugate Combined with Anti-PD-(L)1 Treatment Eliminates HHER2+ Tumors in HPD-1 Transgenic Mouse Model and Contributes Immune Memory Formation. Breast Cancer Research and Treatment 191, 51-61.
https://doi.org/10.1007/s10549-021-06384-4

has been cited by the following article:

• TITLE: Antibody-Coupled Drugs in HER2-Positive Gastric Cancer

  AUTHORS: Baofeng Liu, Yuanmei Dai, Xiaohui Shen, Xiangyang Tian

  KEYWORDS: Antibody-Coupled Drugs, HER2-Positive Gastric Cancer, Review

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.11 No.7, July 7, 2023

  ABSTRACT: Antibody drug conjugates (ADCs) are a new class of drugs that combine chemosynthetic drugs with antibody drugs through a linker. Antibody drug conjugates combine the targeting characteristics of traditional antibody drugs with the cytotoxic characteristics of small molecule drugs, while reducing the side effects of both drugs, making them a kind of “biological missile” and representing a relatively new and evolving class of anti-cancer drugs. Antibody-coupled drugs are currently used in many solid tumors, and this article reviews the clinical application of antibody-coupled drugs in HER2-positive gastric cancer.